63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05685420 (ClinicalTrials.gov) | January 23, 2023 | 6/1/2023 | Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia | Extension Study of Herombopag in Children and Adolescents With Chronic Primary Immune Thrombocytopenia | Immune Thrombocytopenia | Drug: Herombopag | Jiangsu HengRui Medicine Co., Ltd. | NULL | Not yet recruiting | 6 Years | 17 Years | All | 117 | Phase 3 | NULL |